Your browser doesn't support javascript.
loading
New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population.
Danilowska, Karolina; Picheta, Natalia; Zyla, Dominika; Piekarz, Julia; Zych, Katarzyna; Gil-Kulik, Paulina.
Afiliación
  • Danilowska K; Student's Scientific Society of Clinical Genetics, Medical University of Lublin, 20-080 Lublin, Poland.
  • Picheta N; Student's Scientific Society of Clinical Genetics, Medical University of Lublin, 20-080 Lublin, Poland.
  • Zyla D; Student's Scientific Society of Clinical Genetics, Medical University of Lublin, 20-080 Lublin, Poland.
  • Piekarz J; Student's Scientific Society of Clinical Genetics, Medical University of Lublin, 20-080 Lublin, Poland.
  • Zych K; Student's Scientific Society of Clinical Genetics, Medical University of Lublin, 20-080 Lublin, Poland.
  • Gil-Kulik P; Department of Clinical Genetics, Medical University of Lublin, 20-080 Lublin, Poland.
J Clin Med ; 13(12)2024 Jun 18.
Article en En | MEDLINE | ID: mdl-38930098
ABSTRACT
Epilepsy is a disorder characterized by abnormal brain neuron activity, predisposing individuals to seizures. The International League Against Epilepsy (ILAE) categorizes epilepsy into the following groups focal, generalized, generalized and focal, and unknown. Infants are the most vulnerable pediatric group to the condition, with the cause of epilepsy development being attributed to congenital brain developmental defects, white matter damage, intraventricular hemorrhage, perinatal hypoxic-ischemic injury, perinatal stroke, or genetic factors such as mutations in the Sodium Channel Protein Type 1 Subunit Alpha (SCN1A) gene. Due to the risks associated with this condition, we have investigated how the latest pharmacological treatments for epilepsy in children impact the reduction or complete elimination of seizures. We reviewed literature from 2018 to 2024, focusing on the age group from 1 month to 18 years old, with some studies including this age group as well as older individuals. The significance of this review is to present and compile research findings on the latest antiseizure drugs (ASDs), their effectiveness, dosing, and adverse effects in the pediatric population, which can contribute to selecting the best drug for a particular patient. The medications described in this review have shown significant efficacy and safety in the studied patient group, outweighing the observed adverse effects. The main aim of this review is to provide a comprehensive summary of the current state of knowledge regarding the newest pharmacotherapy for childhood epilepsy.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2024 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Clin Med Año: 2024 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Suiza